Drug intelligence / Profile preview

ArmiVET

Development stage: Unknown
Lead developer: Armis Biopharma
Modality: Antimicrobial Peptides → Native Peptides → Peptides
Administration: Topical

Overview

**ArmiVET** is a commercially marketed veterinary topical wound-care spray from Armis Biopharma. It is used for washing or rinsing surgical wounds, cuts, scrapes, sores, and skin irritations in animals, including use on skin, nose, ears, paws, hooves, fur, and hair. The proprietary, non-systemic formulation is intended to cleanse and debride wounds, moisturize damaged tissue, reduce local irritation and inflammation, and provide broad antimicrobial support. Armis Biopharma positions the product within its Veriox technology platform, which the company describes as a peracid/hydrogen peroxide-based antimicrobial and antitoxin platform. ([armisbiopharma.com](https://armisbiopharma.com/wp-content/uploads/ArmiVet-Info-Sheet.pdf))

Brand names: ArmiVET

Beyond the preview

Go deeper on ArmiVET.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArmiVET.

Explore the full profile